Key result
Dual therapy with clopidogrel and aspirin in asymptomatic patients significantly increased cardiovascular death compared to aspirin alone (3.9% vs 2.2%; P=0.001).
Why the study?
Does dual therapy with clopidogrel and aspirin increase cardiovascular mortality compared to aspirin alone in asymptomatic primary prevention patients?
Population
3284 asymptomatic primary prevention patients (based on the second analysis of the CHARISMA trial)
Comparison
Dual therapy with clopidogrel and aspirin vs Aspirin alone
Design
Editorial
Authors
Loading...
In asymptomatic primary prevention patients, dual antiplatelet therapy with clopidogrel and aspirin significantly increases cardiovascular mortality compared to aspirin alone, highlighting the potential dangers of overly aggressive antiplatelet strategies.
Does dual therapy with clopidogrel and aspirin increase cardiovascular mortality compared to aspirin alone in asymptomatic primary prevention patients?
Absolute Event Rate: 3.9% vs 2.2%
p-value: p=0.001
In asymptomatic primary prevention patients, dual antiplatelet therapy with clopidogrel and aspirin significantly increases cardiovascular mortality compared to aspirin alone, highlighting the potential dangers of overly aggressive antiplatelet strategies.
V. L. Serebruany (2007) conducted an editorial in Asymptomatic patients (primary prevention) (n=3,284). Clopidogrel and aspirin vs. Aspirin alone was evaluated on Cardiovascular death (p=0.001). Dual therapy with clopidogrel and aspirin in asymptomatic patients significantly increased cardiovascular death compared to aspirin alone (3.9% vs 2.2%; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: